VistaGen on go with mid-stage study of AV-101 in Parkinson’s; shares up 8%

VistaGen on go with mid-stage study of AV-101 in Parkinson’s; shares up 8%
in Parkinson's disease (PD) patients. The primary endpoints of the 20-subject study are peak score and area-under-curve (AUC) values at day 14 related to a scale called UDysRS. Separately ... read more
Source: Bing NewsPublished on 2020-01-30